Open AccessIn Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe
Author(s) -
Cecília G Carvalhaes,
Leonard R Duncan,
Wen Wang,
Hélio S. Sader
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01195-20
Subject(s) - staphylococcus aureus , potency , staphylococcus , microbiology and biotechnology , enterococcus , in vitro , gram , liter , micrococcaceae , gram positive bacteria , antibacterial agent , enterococcus faecalis , biology , bacteria , medicine , antibiotics , biochemistry , genetics , endocrinology
Contezolid, a new oxazolidinone antibacterial agent currently in development for the treatment of skin and skin structure infections, was susceptibility tested against Gram-positive clinical isolates ( n = 1,211). Contezolid demonstrated potent activity against Staphylococcus aureus (MIC 50/90 , 0.5/1 mg/liter), coagulase-negative Staphylococcus (MIC 50/90 , 0.25/0.5 mg/liter), Enterococcus spp. (MIC 50/90 , 0.5/1 mg/liter), and streptococci (MIC 50/90 , 1/1 mg/liter). Moreover, methicillin-resistant S. aureus and vancomycin-resistant Enterococcus faecium isolates were all inhibited by contezolid at ≤1 mg/liter. These results support the clinical development of contezolid.